This is a variable length study to evaluate the efficacy and safety of
budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma
inadequately controlled with standard of care.
This is a randomized, double-blind, double dummy, parallel group, multicenter 24 to 52 week
variable length study to assess the efficacy and safety of budesonide, glycopyrronium, and
formoterol fumarate metered dose inhaler (MDI) relative to budesonide and formoterol fumarate
MDI and Symbicort pressurized MDI in adult and adolescent participants with inadequately
controlled asthma. Approximately 2800 participants will be randomized globally.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.